Source: International Congress 2014 – ERS/JAMA lunchtime session: 2014 highlights
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
F. Barbe Illa (Lleida, Spain). Treating obstructive sleep apnoea to improve control of hypertension. International Congress 2014 – ERS/JAMA lunchtime session: 2014 highlights

Member's Comments

No comment yet.

Related content which might interest you: Hypertension and obstructive sleep apnoea Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases Year: 2006 Effect of obstructive sleep apnea on asthma control Source: Virtual Congress 2020 – Clinical parameters in severe asthma Year: 2020 Ato-oxy as the first successful pharmacotherapy for obstructive sleep apnoea Source: International Congress 2019 – New horizons for pharmacotherapy of sleep-disordered breathing: from bench to bedside Year: 2019 Unrecognised hypertension in patients screened for obstructive sleep apnoea Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005 Investigating for dyslipidemia in those being referred for suspected obstructive sleep apnoea Source: Annual Congress 2011 - Obstructive sleep apnoea: clinical aspects I Year: 2011 Recommendations for the management of patients with obstructive sleep apnoea and hypertension Source: Guidelines 2013 Year: 2013 Unrecognised systemic hypertension in patients with obstructive sleep apnoea Source: Eur Respir J 2006; 28: Suppl. 50, 643s Year: 2006 Pulmonary hypertension and obstructive sleep apnea syndrome -Marmara Universitypediatric sleep laboratory experience Source: Virtual Congress 2020 – Respiratory physiology and sleep: what is new? Year: 2020 Improving adherence to treatment in patients with obstructive sleep apnoea Source: International Congress 2019 – Treatment of continuous positive airway pressure and monitoring of its effects Year: 2019 Can leptin be used to treat obstructive sleep apnoea? Source: International Congress 2019 – New horizons for pharmacotherapy of sleep-disordered breathing: from bench to bedside Year: 2019 Metabolic disturbances in overlap syndrome (obstructive sleep apnoea + chronic obstructive pulmonary disease) and obstructive sleep apnoea (OSA) patients Source: Annual Congress 2010 - Clinical aspects of sleep apnoea Year: 2010 Treatment control in risk patients with obstructive sleep apnea syndrome Source: Eur Respir J 2006; 28: Suppl. 50, 411s Year: 2006 Resistant arterial hypertension and obstructive sleep apnea syndrome Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA II Year: 2012 Masked hypertension and obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2006; 28: Suppl. 50, 416s Year: 2006 Predictors of hypercapnia in obstructive sleep apnoea (OSA) Source: Annual Congress 2010 - Lung disease and mountain sickness: the importance of ventilatory control Year: 2010 Treatment of obstructive and central sleep apnoea in heart failure: practical options Source: Eur Respir Rev 2007; 16: 183-188 Year: 2007 Prevalence of obstructive sleep apnea among patients with resistant arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 115s Year: 2005 Incidence of cardiovascular complications in overlap syndrome (obstructive sleep apnoea + chronic obstructive pulmonary disease) and obstructive sleep apnoea (OSA) Source: Annual Congress 2007 - Sleep apnoea in cardiorespiratory disorders Year: 2007 Does auto-CPAP improve the quality of sleep in obstructive sleep apnoea (OSA)? Source: Eur Respir J 2001; 18: Suppl. 33, 418s Year: 2001